CIN No. : L24230TG1995PLC020093
CONCORD DRUGS LIMITED
Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.
Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074
E-mail : concorddrugsltd@gmail.com Ph.No : +91 9052779505 Website : www.concorddrugs.in

Date: 10.08.2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400001.

Scrip Code: 538965

Sub: Outcome of Board Meeting held on 10.08.2026 pursuant to Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company was held on Monday, 10th August 2026, wherein the Board inter alia:

1. Considered and approved the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter ended 30th June, 2026.
2. The Board took note of the Limited Review Report issued by the Statutory Auditors of the Company on the aforesaid financial results.

Further, the financial results are also available on the website of the Company at Concord Drugs Limited > Investor Relations and on the website of BSE Limited.

The financial results will also be published in the newspapers as per the requirements and in the format prescribed under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 04:00 PM and concluded at 05:00 PM.

This is for your information and records.

Thanking you,

Yours faithfully,

For Concord Drugs Limited

Seelam Nagi Reddy
Digitally signed by Seelam Nagi Reddy
Date: 2026.08.10 17:21:51 +05'30'

Nagi Reddy Seelam
Managing Director
DIN: 01764665

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30th June 2026

[Rs. in Lakhs]

	Particulars	Quarterly ended			Year Ended
		30-Jun-26 (Un Audited)	31-Mar-26 (Audited)	30-Jun-25 (Un Audited)	31-Mar-26 (Audited)
I	Revenue from Operations				
	a. Net sales from Operations	2,088.86	3,555.22	1,338.35	7,584.86
	b. Other Operating Income	0.82	1.08	-	3.44
II	Other Income				
III	Total Revenue (I+II)	2,089.68	3,556.31	1,338.35	7,588.30
IV	Expenses				
	a.Cost of Material Consumed	1,653.49	3,180.79	1,068.92	6,449.85
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	38.98	7.08	60.64	63.98
	c. Employees Benefit Expenses	124.57	172.61	87.11	489.91
	d. Finance Costs	35.11	34.46	41.99	145.91
	e. Depreciation and Amortisation expense	34.76	35.05	36.55	135.72
	f. Other expenses	48.52	52.85	27.94	158.07
	Total Expenses	1,935.42	3,482.84	1,323.15	7,443.44
	Profit/ (Loss) before Exceptional item and tax (III-IV)	154.26	73.47	15.20	144.86
V	Exceptional Items	-			-
VI	Profit/ (Loss) before tax (V-VI)	154.26	73.47	15.20	144.86
VII	Tax Expense:	43.04	21.79	4.06	41.12
VIII	a. Current tax	44.11	21.32	5.15	41.34
0	b. Deferred tax charge/credit	-1.08	0.47	-1.09	-0.22
IX	Profit/ (Loss) for the period (VII-VIII)	111.23	51.68	11.14	103.74
X	Other Comprehensive Income	-	-	-	-
	Items that will not be reclassified to profit or loss	-	-	-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	111.23	51.68	11.14	103.74
XI	Paid up Capital	1,317.50	1,317.50	1,000.00	1,317.50
	(Face value of the share- Rs. 10 each)				
	Other Equity	3,645.12	3,533.89	2,422.50	3,533.89
XII	Earnings per share (of Rs. 10 each) (in Rupees)	(not annualised)	(not annualised)	(not annualised)	(annualised)
XIII	a. Basic (in Rs)	0.84	0.46	0.11	0.93
	b. Diluted (in Rs)	0.84	0.46	0.11	0.93

Notes:

1	The finnacial results of the company hav been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
2	The above standalone financial results as reviwed by the audit committee have been approved by Board of Directors at its meeting held on 10th August 2026
3	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
4	The Earnings Per Share (EPS) for the quarter ended is not strictly comparable on a Quarter-on-Quarter (QoQ) and Year-on-Year (YoY) basis, as the weighted average number of equity shares outstanding increased during quarter ended 31.03.2026 pursuant to the allotment of 31,75,000 equity shares at ₹36.50 per share through a preferential issue. Notwithstanding the increase of over 33% in the Company's equity share capital, the EPS has improved during the quarter. This improvement reflects the fact that the growth in profitability has more than outpaced the increase in the equity share base, demonstrating stronger earnings generation despite the dilution arising from the preferential allotment.
5	The results are also available on the webiste of the Company www.concorddrugs.in

Concord Drugs Limited
Hyderabad

By Order of the Board
For Concord Drugs Limited

Nagi Reddy Seelam
Managing Director
DIN: 01764665

Place: Hyderabad
Date: 10.08.2026

STATEMENT OF UN AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30th June 2026

[Rs. in Lakhs]

	Particulars	Quarterly ended			Year Ended
		30-Jun-26 (Un Audited)	31-Mar-26 (Audited)	30-Jun-25 (Un Audited)	31-Mar-26 (Audited)
I	Revenue from Operations				
	a. Net sales from Operations	2,093.88	3,788.80	1,360.64	7,873.68
	b. Other Operating Income	0.82	1.08	-	3.44
II	Other Income				
III	Total Revenue (I+II)	2,094.70	3,789.89	1,360.64	7,877.13
IV	Expenses				
	a.Cost of Material Consumed	1,652.38	3,507.05	1,081.22	6,802.96
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	38.98	-95.28	60.64	-38.37
	c. Employees Benefit Expenses	125.58	175.26	88.60	497.05
	d. Finance Costs	39.61	39.57	49.00	171.37
	e. Depreciation and Amortisation expense	34.93	35.28	36.78	136.67
	f. Other expenses	48.73	53.24	28.55	160.13
	Total Expenses	1,940.21	3,715.13	1,344.81	7,729.81
	Profit/ (Loss) before Exceptional item and tax (III-IV)	154.49	74.76	15.83	147.32
V	Exceptional Items	-	-	-	-
VI	Profit/ (Loss) before tax (V-VI)	154.49	74.76	15.83	147.32
VII	Tax Expense:	43.10	21.96	4.07	41.82
VIII	a. Current tax	44.15	21.66	5.34	41.98
0	b. Deferred tax charge/credit	-1.06	0.30	-1.27	-0.16
IX	Profit/ (Loss) for the period (VII-VIII)	111.40	52.80	11.77	105.50
X	Other Comprehensive Income	-	-	-	-
	Items that will not be reclassified to profit or loss	-	-	-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	111.40	52.80	11.77	105.50
XI	Paid up Capital	1,317.50	1,317.50	1,000.00	1,317.50
	(Face value of the share- Rs. 10 each)				
	Other Equity	3,645.12	3,533.89	2,422.50	3,533.89
XII	Earnings per share (of Rs. 10 each)(in Rupees)	(not annualised)	(not annualised)	(not annualised)	(annualised)
XIII	a. Basic (in Rs)	0.85	0.47	0.12	0.95
	b. Diluted (in Rs)	0.85	0.47	0.12	0.95

Notes:

1	The finnacial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
2	The above Consolidated financial results as reviwed by the audit committee have been approved by Board of Directors at its meeting held on 10.08.2026
3	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
4	The Earnings Per Share (EPS) for the quarter ended is not strictly comparable on a Quarter-on-Quarter (QoQ) and Year-on-Year (YoY) basis, as the weighted average number of equity shares outstanding increased during quarter ended 31.03.2026 pursuant to the allotment of 31,75,000 equity shares at ?36.50 per share through a preferential issue. Notwithstanding the increase of over 33% in the Company's equity share capital, the EPS has improved during the quarter. This improvement reflects the fact that the growth in profitability has more than outpaced the increase in the equity share base, demonstrating stronger earnings generation despite the dilution arising from the preferential allotment.
5	The results are also available on the webiste of the Company www.concorddrugs.in

Concord Drugs Limited ★ Hyderabad ★

By Order of the Board
For Concord Drugs Limited

Nagi Reddy Seelam
Managing Director
DIN: 01764665

Place: Hyderabad
Date: 10.08.2026

PUNDARIKASHYAM AND ASSOCIATES
CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet, Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033
E-mail : info@pkas.in / infoong@pkas.in
GSTIN : 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34,Interim Financial Reporting('Ind AS 34'),prescribed under section 133 of the Companies Act, 2013 ('the act'),SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'),and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

PUNDARIKASHYAM & ASSOCIATES HYDERABAD Chartered Accountants

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement,prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pundarikashyam And Associates
Chartered Accountants
FRN:011330S

B. Surya Prakasa Rao

PUNDARIKASHYAM & ASSOCIATES HYDERABAD Chartered Accountants

B Surya Prakasa Rao
(Partner)
MNo: 205125
UDIN : 26205125FVTUHT7813.

Place: Hyderabad
Date: 10.08.2026

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of Consolidated unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34,Interim Financial Reporting('Ind AS 34'),prescribed under section 133 of the Companies Act, 2013 ('the act'),SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'),and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

PUNDARIKASHYAM & ASSOCIATES
HYDERABAD
Chartered Accountants

4. The Statement includes the results of the following entities:
   Proton Remedies Private Limited

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
   one subsidiary, whose unaudited interim financial results include total revenues of Rs 36.54 lakhs, total net profit after tax of Rs.0.23 lakhs, for the quarter ended June 30, 2026, as considered in the Statement which have been reviewed by their respective independent auditors. The independent auditor's reports on unaudited interim financial results and other financial information of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of this subsidiary is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to our reliance on the work done and the reports of the other auditors.

For Pundarikashyam and Associates
Chartered Accountants
FRN:011330S

PUNDARIKASHYAM & ASSOCIATES HYDERABAD Chartered Accountants

B. Surya

B Surya Prakasa Rao
(Partner)
MRNo: 205125
UDIN: 26205125CEEBMR8295.

Place: Hyderabad
Date: 10.08.2026.